Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia-Reference-Cited by-同舟云学术

Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia

Published:2017-02-15 Issue:3 Volume:79 Page:629-633
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nishikawa Yoshitaka^ORCID,Funakoshi Taro,Horimatsu Takahiro,Miyamoto Shin’ichi,Matsubara Takeshi,Yanagita Motoko,Nakagawa Shunsaku,Yonezawa Atsushi,Matsubara Kazuo,Muto Manabu

Funder

Kyoto University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-017-3249-1.pdf

Reference16 articles.

1. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664

2. Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155–160. doi: 10.1001/archneur.1970.00480260061008

3. Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465

4. Nakamura M, Kobashikawa K, Tamura J et al (2009) A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer. Nihon Shokakibyo Gakkai Zasshi 106:1744–1750. doi: 10.11405/nisshoshi.106.1744

5. Misumi N, Goto T, Miyoshi T et al (2013) Risk factors for hyperammonemia during mFOLFOX6 treatment. Gan To Kagaku Ryoho 40:483–487

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case Report of Successful Treatment with Dose-controlled mFOFOX6+Bevacizumab for Metastatic Colorectal Cancer in Patient Receiving Hemodialysis;YAKUGAKU ZASSHI;2024-08-01

2. Impaired Consciousness Due to Hyperammonemia During S-1 Administration for Unresectable Pancreatic Cancer;Internal Medicine;2024

3. Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure;Cancer Chemotherapy and Pharmacology;2023-08-22

4. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022;International Journal of Clinical Oncology;2023-08-12

5. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database;Cancer Chemotherapy and Pharmacology;2023-05-19